The preventive effect of inhaled antibiotic against ventilator-associated pneumonia: A systematic review and meta-analysis.

Background: Ventilator-associated pneumonia (VAP) constitutes a considerable challenge for patients in intensive care units (ICUs) and necessitates the development of effective preventive strategies. This study aimed to evaluate the clinical efficacy of inhaled antibiotics for preventing VAP.
Methods: PubMed, Embase, and ClinicalTrials.gov were searched until 21 January 2024. Randomized controlled trials investigating the clinical efficacy of inhaled antibiotics for VAP prevention were included.
Results: Seven randomized controlled trials, involving 1465 patients, of whom 734 were classified as the study group receiving inhaled antibiotics and 731 as the control group receiving placebo were included in this meta-analysis. Overall, the occurrence of VAP was significantly lower in the study group than in the control group (risk ratio, 0.69; 95% confidence interval [CI], 0.51-0.92). However, there were no significant differences in mortality (risk ratio, 0.90; 95% CI, 0.74-1.09), length of stay in ICU (mean difference [MD], 0.10 d; 95% CI, -0.91 to 1.1), and hospital (MD, 0.30 d; 95% CI, -1.82 to 2.43), and mechanical ventilation duration (MD, 0.45 d; 95% CI, -0.45 to 1.35) between groups.
Conclusions: Inhaled antibiotics hold promise for mitigating the risk of VAP among critically ill patients. However, their impact on mortality, length of stay in ICU and hospital, and mechanical ventilation duration was not statistically significant.
Competing Interests: Declaration of competing interests All authors affirm that no conflict of interest exists.
(Copyright © 2024 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)